Sentence examples for trials objective from inspiring English sources

Due to the mechanism of action of new drugs, cytostatic more than cytotoxic at least in principle, the usual endpoint of phase II trials, objective response rate, is now often replaced by alternative event-related endpoints, such as progression-free survival or progression-free rate at a fixed time-point.

In all three trials, objective responses have been observed.

Additionally, in two compassionate use trials, objective response rates between 14% and 51% were seen, the largest response resulting from a study specifically focusing on liposarcoma.

In phase I clinical trials, objective responses were observed in patients with melanoma, renal cell carcinoma, and non-small cell lung cancer, who underwent immunotherapy with an anti-PD-1 monoclonal antibody [ 169– 169].

In phase II trials, objective response rates to ixabepilone monotherapy ranged from 11.5% in patients with MBC resistant to anthracyclines, taxanes, and capecitabine [ 27] to 57% in MBC patients previously untreated with taxanes [ 36].

First line triplet regimens of chemotherapeutic drugs, or doublet associated to bevacizumab (BEV) or cetuximab, reported in phase III trials objective response rate (ORR) 39%68%%, progression-free survival (PFS) 7.2 10.6 months, and overall survival (OS) 19.9 26.1 months [ 2, 4, 6– 8].

The trial objective was to test whether a new mechanism of action would effectively treat migraine headaches and to select a dose range for further investigation.

The trial objective was to study the efficacy of beta-glucan on lymphocyte viability and plasma IL-18 of weaning piglets.

The FIDEL trial objective is to evaluate the impact of a therapeutic strategy based on the early administration of human fibrinogen concentrate compared to the current practice based on late administration in severe PPH patients requiring second line uterotonics.

In this trial, objective responses to paclitaxel were seen in only 4.4% of patients treated.

The pre-specified primary immunological trial objective was to evaluate induction of autologous WT1-specific T cell responses.